Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.55 USD | -3.14% | +1.07% | +11.85% |
05-14 | Oppenheimer Cuts Fulcrum Therapeutics Price Target to $14 From $16, Maintains Outperform Rating | MT |
05-14 | Goldman Sachs Upgrades Fulcrum Therapeutics to Buy From Neutral, Price Target is $15 | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.85% | 469M | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- FULC Stock
- News Fulcrum Therapeutics, Inc.
- Transcript : Fulcrum Therapeutics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-11-2023 04